ARTICLE | Clinical News
LY900009: Phase I data
May 28, 2012 7:00 AM UTC
A dose-escalation Phase I trial in 22 patients with advanced cancer showed that 60 mg LY900009 led to grade 3 dose-limiting toxicities (DLTs) of fatigue and diarrhea in 2 patients. The maximum tolerat...